Cancer Survival Disparities For Most Minority Populations Increase As Cancers Become More Treatable
Main Category: Breast CancerAlso Included In: Prostate / Prostate Cancer; Cancer / Oncology
Article Date: 18 Dec 2009 - 3:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Racial and ethnic disparities in cancer survival are greatest for cancers that can be detected early and treated successfully, including breast and prostate cancer, according to a study by researchers at Columbia University's Mailman School of Public Health and Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital. Disparities are small or nonexistent for cancers that have more limited early detection and treatment options, such as pancreatic and lung cancer.
The findings, published in the October 2009 issue of Cancer Epidemiology, Biomarkers, and Prevention, highlight the need to develop specific health policies and interventions to address social disparities.
Although prior studies have focused on factors that contribute to disparities in specific cancers, the Mailman School researchers' goal in this study was to understand why racial/ethnic disparities emerge in some cancers but not others. The study used data from more than 580,000 cancer cases in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries to compare racial/ethnic differences in survival across a spectrum of cancers, classified according to their five-year relative survival rates as a measure of how amenable each cancer is to medical interventions. The authors hypothesized that racial/ethnic disparities increase as medical interventions improve overall survival because individuals with more socioeconomic resources are in a better position to exploit medical advances to protect their health.
The results found that, as compared with whites, substantial survival disparities existed in more treatable cancers in African-Americans, American Indians/Alaska Natives, Hispanics, and several subgroups of the Asian/Pacific Islander population.
"Our findings may seem counterintuitive at first since medical advances in the last few decades have resulted in substantial improvements in cancer survival for most racial/ethnic population groups. However, this enhanced capacity to successfully treat certain cancers, when combined with the social disadvantage faced by many minorities, can lead to greater relative differences in cancer survival by race and ethnicity," said Parisa Tehranifar, DrPH, assistant professor of Epidemiology, a member of the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital and the Mailman School of Public Health's Center for the Study of Social Inequalities in Health and lead author of the paper.
"If we are correct in our interpretation that these disparities emerge as a result of greater utilization of available interventions by socially advantaged groups, it follows that interventions that are easy to access and use, and do not rely heavily on personal resources such as educational and income levels, may have the greatest potential for reducing cancer and other health disparities," noted Dr. Tehranifar.
"Our cancer prevention and treatment efforts should continue to advance our public health and medical capacity for lowering the burden of cancer and mortality. However, we must also pay close attention to how the benefits of our medical advances are distributed in the population, and implement specific strategies that can reduce cancer disparities," said Mary Beth Terry, PhD, associate professor of Epidemiology, a co-leader of the Cancer Epidemiology Program at the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital, and senior author of the paper.
Supported by a Lance Armstrong Foundation Young Investigator Award and a postdoctoral fellowship from the National Cancer Institute, the research was done in collaboration with: Dr. Alfred I. Neugut, MD, PhD; Myron Studner Professor of Cancer Research in the Department of Medicine and professor of Epidemiology, and leader of the Prevention, Control & Disparities Program at the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital; Jo C. Phelan, PhD, associate professor of Sociomedical Sciences; and Bruce G. Link, PhD, professor of Sociomedical Sciences and Epidemiology. Drs. Phelan and Link are also co-directors of Mailman School's Center for the Study of Social Inequalities and Health.
Source: Stephanie Berger
Columbia University's Mailman School of Public Health
Visit our breast cancer section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/174445.php>
APA
http://www.medicalnewstoday.com/releases/174445.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




